Background: Hepatitis C virus (HCV) infection is a major health issue for HIV-infected patients. The high cost of new direct-acting antivirals against HCV limit their use in countries with poor income, underscoring the urgent medical need of an HCV vaccine. The impact of HIV infection on the HCV-humoral response remains unknown although it might greatly influence the design and the effectiveness of an HCV vaccine in HIV-infected patients. The aim of this study is to analyze the HCV-specific neutralizing response in HIV-infected patients. Methodology: HCV-specific neutralizing antibody-mediated response was assessed in a cohort of 299 patients including 136 HIV-/HCV+, 70 HIV+/HCV-, and 63 HIV+/HCV+. Thirty healthy HCV-unexposed controls were used to define neutralization assay cutoff. Neutralization experiments were performed with patients’ sera and purified immunoglobulins G (IgG) using HCV pseudoparticles (HCVpp) and cell-culture derived HCV (HCVcc) model systems. Results: Mean age of HIV-/HCV+ and HIV+ patients was 49 and 43 years, respectively. Sixty-five (49%) HIV+ patients have detectable HIV RNA in plasma with a mean viral load at 3.96 (1.72- 5.83) log10 copies/mL. Mean CD4+ cell count in all HIV+ patients were 490 (41-1770) cell/mm3. HCV RNA was detectable in 70% of HIV-/HCV+ and 57% of HIV+/HCV+ patients, with a mean HCV RNA load at 5.96 (4.38-7.15) and 5.83 (1.51-7.24) log10 copies/mL, respectively (p=0.59). High levels of neutralizing antibodies (nAbs) were detected in 97% of HCV-viremic HIV+/HCV+, among them 69% harbored nAbs against the three HCVpp genotypes 1a, 1b, and 3a, similarly to HCV-viremic HIV-/HCV+ patients (95% and 65%, respectively, p>0.05). In HCV-aviremic patients, high levels of nAbs were more frequently noticed in HIV+/HCV+ (85% against at least one genotype and 15% against the three genotypes) than in HIV-/HCV+ individuals (44% and 7%, respectively), (p<0.001). Moreover, broadly nAbs anti-HCV were detected in 13% of HIV+/HCV- individuals. All the data were confirmed using HCVcc model system. No correlation was observed between nAbs and HIV RNA load or CD4+ cell count. Conclusions: Our results indicate that HIV-infected patients are able to develop high levels of HCV-specific broadly nAbs. Persistence of nAbs in HCVaviremic HIV+/HCV+, and the detection of neutralizing activity in HIV+/HCV- patients suggest that they may have experienced frequent exposure to HCV as observed in HIV-negative individuals (e.g injection drug users) with the immune capacity to clear HCV. These data suggest that HCV-humoral response is not impaired during HIV-infection. The persistence of a broad HCV-neutralizing response in HIV+ patients may forecast promising achievement of HCV vaccination in HIV-infected persons.